RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MRTX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

FAQ

What is the symbol for Mirati Therapeutics Stock and on which exchange is it traded?
The symbol for Mirati Therapeutics is MRTX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Mirati Therapeutics Stock?
Mirati Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Mirati Therapeutics Stock?
Mirati Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Mirati Therapeutics Stock.

What's the current price of Mirati Therapeutics Stock?
As of the end of day on the 2024-03-28, the price of an Mirati Therapeutics (MRTX) share was $58.70.

What is the 52-week high and low for Mirati Therapeutics Stock?
The 52-week high for Mirati Therapeutics Stock is $64.41 and the 52-week low is $27.30.

What is the market capitalization of Mirati Therapeutics Stock?
As of the 2024-03-28, the market capitalization of Mirati Therapeutics is 4.118B.

When is the next earnings date for Mirati Therapeutics?
The upcoming earnings date for Mirati Therapeutics is May 07, 2024.
Click to get the best stock tips daily for free!

About Mirati Therapeutics

Mirati Therapeutics Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical tr... MRTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT